| Pullan's Pieces #48 | Some Pharma Companies Need to In-License in Oncology Now |
| | My highlights from the Buzz from ASCO |
| | Diagnostic Acquisitions in 2010 |
| | Genmark Diagnostics does IPO |
| | Free Forums to pitch to Angels |
| Pullan's Pieces #47 | Late Stage Trials and No Partner (LSTNOP) – a report from our BIO panel |
| | Biomarkers and Biobanking – a report from our BIO panel. |
| | Massive pathway alterations in clear cell renal carcinoma |
| | VC investment 1st quarter 2010 – decline in $ and in A rounds |
| | Who funds most companies? |
| Pullan's Pieces #46 | A snapshot of drugs in Phase 3 and preregistration; unpartnered snapshot coming at BIO panel |
| | U.S. Healthcare Reform – biosimilars |
| | U.S. Healthcare Reform – outcomes research |
| | Myriad genes and genetic tests are not patentable |
| Pullan's Pieces #45 | Patent expirations driving company acquisitions |
| | The Challenges of NICE cost-effectiveness – it depends on the comparison |
| | First biomarker rescue of a drug? |
| | PSA screening for prostate cancer “a waste”, says inventor |
| | FDA Advisory Committee members say “not sufficient evidence of efficacy”, but recommend approval |
| Pullan's Pieces #44 | Pharma Companies look to generics to hold on to more $ after patent expirations, and to grow in emerging markets |
| | Top 10 Product Deals of 2009 |
| | Biotech IPO’s uncertain, M&A probable |
| Pullan's Pieces #43 | What to look for in 2010? |
| | Pfizer shares risk with Debio on CTLA-4 antibody deal |
| | Cost Effectiveness of End of Life treatments at debate at UCLA Medical Center |
| Pullan's Pieces #42 | Unpopular Sarbannes-Oxley up for review at the Supreme Court |
| | Recap on current trends in financings of biotech and pharmaceutical companies |
| Pullan's Pieces #41 | China: new support for innovation |
| | China: Recent Product deals |
| | China’s clinical development pipeline |
| | Many proteins bind to DNA in addition to their known roles |
| | BioEurope panel presentation and coverage by EBD Group |
| Pullan's Pieces #40 | Client News: Neumedicines gets a big grant. Zenobia gets covered by Neurotech Insights. |
| | “How Personalized Medicine Could Change Oncology Deals” at BioEurope (Monday November 2nd) |
| | US Patent Office drops rules restricting number of number of claims and continuations |
| | Breast Cancer Whole Genome Sequenced – not like AML story |
| | Big Pharma Continues to Innovate – Roche goes to Russia; GSK sets up Virtual POC unit |
| | Analysis of Daiichi Arqule Deal – see www.pullanconsulting.com |
| | Shifts in funding - Follow-on share offerings up, M&A down, Big Pharma licensing flat, Corporate VCs active earlier, VC funds down |
| | Help after the deal is signed? |
| Pullan's Pieces #39 | Special offer on useful book: Biopreneurs: The Molecular Millionaires |
| | Client News: A Deal for ImmmunoCellular Therapeutics and Roche |
| | How much delay is there for launch of new drugs in Japan? |
| | Personalized medicine shocker: Failure to test for Her2 in breast cancer |
| | Market exclusivity for the leader in a new class of drugs is shorter than ever |
| | Analysis Daiichi Sankyo Arqule cancer deal with Foley |
| | Foley's Life Science Congress, panel |
| Pullan's Pieces #38 | Cell Therapy for Cancer – J&J does a CRADA; a status report on cell therapies in the pipeline |
| | Signs of optimism: an IPO, new public stock offerings; a BIO and Thomson Reuters survey; Cooley Goodard on private company financings |
| | Genomic sequence conservation does not always imply critical function |
| Pullan's Pieces #37 | VC Funding Up in June |
| | Licensing deals are getting done |
| | 2008 deal terms from Evaluate Pharma |
| | Royalty Rates from Deloitte Recap |
| | Most partners do stick together for the contracted period |
| | Drug development after termination a source of real value |
| Pullan's Pieces #36 | Patent expiration in major pharmas |
| Pullan's Pieces #36 | J&J Partnering Profile |
Pullan's Pieces #35 | How many gene variations contribute to common diseases? |
| Pullan's Pieces #35 | Deal Analysis: Indication Splitting in the Immunomedics Nycomed License for anti-CD20 Antibody |
| Pullan's Pieces #34 | New Venture Money in the 1st Quarter of 2009 |
| Pullan's Pieces #34 | VC Funding of Biotech Therapeutics, Seed and A Rounds in the 1st Quarter of 2009 |
| Pullan's Pieces #33 | A partnering profile of Eli Lilly |
| Pullan's Pieces #32 | Big expectations from analysts, but many of forecasted top products of 2008 fail to launch as expected |
| Pullan's Pieces #31 | A partnering profile of GSK |
| Pullan's Pieces #30 | Twins with a lipid storage disease may shed light on Alzheimer’s – a touching story, with hope from foundations and a patient-funded virtual biotech |
| | Most cases of relapse in Acute Lymphoblastic Leukemia can be traced back to a cell with a mutation existing at diagnosis |
| | New doubt on cancer stem cell hypothesis, at least in melanoma |
| | Cheaper proteins may reduce the costs of biologic drugs; Merck sees yeast production as enabling biogenerics business |
Pullan's Pieces #29 | The economy and biotech |
| | The FDA vouchers for Priority Review |
| | Gene expression to characterize cancer of unknown primary origin |
Pullan's Pieces #28 | When must you take a license to IP on Research Tools under the Hatch-Waxman Safe Harbor? |
| | What is enough to describe the application of gene sequence patents? |
Pullan's Pieces #27 | A strong case for genotyping in patient treatment with warfarin, still not ready for wide use? |
| | 4th tiers in drug insurance payments –patients paying a percentage of the costs of expensive drugs |
| | VC-backed firms may become eligible for SBIR grants |
| | UK cancer care continues to be scary |
Pullan's Pieces #26 | Antibiotic resistance could exist before the drug is dosed! |
| | Factors driving success in specialty pharma? |
| | Picking biopartnering meetings to attend |
| | Patient-sponsored drug research and development |
| Pullan's Pieces #25 | VC’s are still raising money. |
| | But exits for VCs are harder. |
| | Drug partnering continues in the 2nd quarter of 2008 |
| | Different scale of manufacturing for approved biologic requires a new BLA, but Insmed pushing for a path for a biologic follow-on. |
| Pullan's Pieces #24 | The number of genes does not reflect the complexity of the “Interactome” |
| | First to market or fast follower? Factors driving market success |
| | Biggest news from ASCO? Erbitux biomarker impact on response. |
| | When is a little cancer too little to worry about? |
| Pullan's Pieces #23 | Flaw in appointing process for patent judges may jeopardize MANY patent decisions |
| | GPCRs as drug targets |
| | The impact of the credit crunch on biotech? |
| | Genes of the Platypus are a fascinating mix of mammal, birds, and reptiles. |
| Pullan's Pieces #22 | Patients Like Me - creating evidence-based medicine as a community of patients |
| | Biotech has a higher failure rate than Pharma in Phase III to Approval |
| | 2 RNAi drugs may have effects through immune system rather than specific gene silencing |
| Pullan's Pieces #21 | The FDA may start missing its review deadlines |
| | Parexel’s Bio/Pharmaceutical R&D Statistical Sourcebook – Good source of industry averages |
| | Companies are expanding their antibody pipelines |
| Pullan's Pieces #20 | A lack of replacement power in the anti-infectives pipeline |
| | Mouse model for the dry form of AMD – a platform for new drugs |
| | Recession impact on biotech? |
| Pullan's Pieces #19 | Top biotech and pharma stories and trends of 2007 |
| | · Changes in US Patent rules and the definition of obviousness changes |
| | · Deal values grow rapidly |
| | · Layoffs in big pharma and big biotech |
| | · India innovates |
| | · Cancer vaccines continue to struggle |
| | · Acquisitions instead of IPOs as exits for VCs |
| | · PDUFA renewal |
| | · Increasing emphasis on safety at the FDA and CMS |
| | · A guarantee of efficacy for reimbursement for Velcade in the UK |
| | |
Pullan's Pieces #18 | Increased lipophilicity in recently synthesized new drug candidates may mean greater attrition in development |
| | A sticky message- simple, concrete and surprising to be remembered and change thinking |
| | |
Pullan's Pieces #17 | Deal Values Grew 45% Annually |
| Fat fear was bad public science |
| Most detailed oncology drugs |
| Biotech tour: Germany, part 1 of 2 |
| |
Pullan's Pieces #16 | Deal Averages |
| The US Patent and Trademark Office tapping the internet to find prior art |
| Polypharmacy the 5th leading cause of death |
| Will continuous manufacturing replace batch manufacturing? |
| Biotech tour: Italy |
| |
Pullan's Pieces #15 | Biotech tour: India |
| A new kinase important in breast cancer? |
| New US patent rules to hurt biotech? |
| Roche wins case against Arizona anti-takeover law in its hostile bid for Ventana Medical Systems |
| |